New CAR-T Therapy Posts a 100% Response Rate — With Notably Fewer Neurological Side Effects — in Advanced Myeloma

What This Article Covers

A Phase 1 study of an experimental CAR-T cell therapy called anito-cel (anitocabtagene autoleucel), published this month in the New England Journal of Medicine, reported that every one of the 38 heavily pretreated multiple myeloma patients in the trial responded to treatment, with roughly 80% reaching complete remission and no delayed neurological complications reported. The therapy is not yet FDA-approved, but the agency has already accepted a Biologics License Application for it, with a decision anticipated by December 23, 2026 — and Gilead's Kite Pharma moved to fully acquire the therapy's co-developer, Arcellx, for as much as $7.8 billion on the strength of this data package.

A Hard Cancer to Treat, and a New Tool Aimed at It

Multiple myeloma is a blood cancer that, despite real progress over the past decade, almost always eventually relapses. Patients who have exhausted standard drug regimens have had two FDA-approved CAR-T options since 2021 and 2022 — Abecma (idecabtagene vicleucel) and Carvykti (ciltacabtagene autoleucel) — both of which target a protein called BCMA on myeloma cells. Both drugs have transformed outcomes for many patients, but both also carry a real risk of neurotoxicity, including rare but serious delayed neurological syndromes that can appear months after infusion. Anito-cel, developed by Arcellx and Kite, targets the same BCMA protein but uses a differently engineered "D-domain" binding component instead of the antibody-derived binder used in the earlier drugs. Researchers at Mass General Brigham's Cancer Institute and the University of Chicago Medicine Comprehensive Cancer Center have been following a small group of patients treated with it for several years, and their newest data — with a median follow-up of well over two years — was published in the New England Journal of Medicine in September 2026.

The Results Researchers Reported

The numbers are, by the standards of relapsed myeloma, striking. All 38 participants — patients who had already failed multiple prior lines of therapy — responded to a single infusion of anito-cel. About 80% achieved a complete response, meaning no detectable evidence of disease by standard testing. More than half of participants remained progression-free at two years, and roughly two-thirds were alive at three years. For a patient population with historically poor outlooks after multiple relapses, durability at that length of follow-up is a meaningful and welcome signal.

Just as important to the researchers was what didn't happen. An investigator on the study at Mass General Brigham was quoted in the hospital's release describing the absence of neurotoxic and inflammatory side effects in the Phase 1 study as particularly encouraging. Serious immune-related and neurological side effects were described as uncommon in this cohort, and no patients developed the severe, delayed neurotoxicity — including Parkinsonism-like syndromes — that has worried clinicians about some existing BCMA-directed CAR-T products.

Why the Safety Signal Is the Real Headline

Efficacy alone would not distinguish anito-cel from the CAR-T therapies already on the market — Carvykti, in particular, has posted very strong response rates in its own trials. What has drawn attention from investors and oncologists alike is the apparent gap in neurological risk. In the larger, registration-focused Phase 2 iMMagine-1 trial (data presented at the American Society of Hematology's December 2025 meeting), researchers reported a 96% overall response rate, with 74% of patients reaching a stringent complete or complete response and 95% testing negative for minimal residual disease — while any-grade neurotoxicity occurred in only about 8% of patients, with no cases of the delayed neurotoxicity syndromes seen with some other CAR-T products. If that safety differentiation holds up in larger, longer studies, it could make CAR-T therapy accessible to patients and treatment centers currently wary of the intensive neurological monitoring current products require, potentially including outpatient administration.

Where Things Stand With Regulators — and Why Industry Is Betting Big

None of this changes the fact that anito-cel remains investigational. It is not FDA-approved, and patients cannot receive it outside of clinical trials or an eventual approved indication. That said, the regulatory path is now concretely underway: the FDA has accepted Kite's Biologics License Application for anito-cel as a fourth-line treatment for relapsed or refractory multiple myeloma, with an anticipated decision date of December 23, 2026. A confirmatory Phase 3 trial, iMMagine-3, comparing anito-cel directly to standard-of-care regimens, is also ongoing. The clearest sign of how seriously the field is taking this data came earlier in 2026, when Gilead Sciences announced it would acquire Arcellx outright — a deal valued at up to $7.8 billion — specifically to gain full control of anito-cel's development. Gilead has described the drug as a potential foundational treatment for multiple myeloma over time, including in earlier lines of therapy, a sign the company sees a future well beyond the current relapsed/refractory setting this month's NEJM paper covers.

Bottom Line

This is genuinely encouraging news out of the cancer immunotherapy field: a peer-reviewed, NEJM-published trial showing a 100% response rate and a favorable neurological safety profile in a group of patients who had run out of good options. But it is still early-stage evidence — a 38-patient Phase 1 study, not a completed pivotal trial, and not yet an FDA-approved therapy. The larger Phase 2 data supporting the pending FDA filing are more mature and reinforce the same signal, and a Phase 3 trial and an FDA decision (expected by the end of December 2026) are the next real tests. Patients with relapsed or refractory myeloma should discuss with their oncologist whether an anito-cel clinical trial, or an already-approved BCMA-directed CAR-T therapy, is appropriate for their situation — this drug is not yet available outside research settings.